Stocks · News reference
Barclays has updated its price target for Axogen, lowering it to $50.00 per share from the previous $55.00, while maintaining an Overweight rating.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Axogen, Inc. announced that its management team will participate in the Canaccord Genuity 20th Annual MedTech, Diagnostics, Digital Health & Services Forum and the Jefferies Global Healthcare conference.
Axogen, Inc. (NASDAQ: AXGN), a peripheral nerve repair solutions company, announced its participation in three investor conferences in November and December 2026, including Canaccord Genuity MedTech Forum, Jefferies Global Healthcare Conference, and Piper Sandler Healthcare Conference. The company will host fireside chats and 1x1 investor meetings at these events, with webcasts available on its investor relations page.
Several major financial institutions, including BofA Securities, Barclays, and Mizuho, raised their price targets for Axogen, Inc. on October 30, 2026.
Leerink Partners reaffirmed its 'Outperform' rating on Axogen, Inc. and increased its price target for the company's stock from $52 to $56.
Multiple financial institutions, including Truist Securities, Barclays, and Wells Fargo, have raised their price targets for Axogen, Inc. following the company's third-quarter 2026 earnings report.